問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
沈佩誼
下載
2025-10-01 - 2028-12-31
Condition/Disease
In NCFBE and chronic PsA transfer subjects, the effect of AZD0292 IV every 4 weeks (Q4W) compared with placebo on the incidence of moderate to severe acute lung exacerbations was evaluated.
Test Drug
AZD0292
Participate Sites7Sites
Recruiting7Sites
2025-10-20 - 2030-07-11
Participate Sites4Sites
Recruiting4Sites
2025-06-09 - 2029-11-26
Participate Sites8Sites
Recruiting8Sites
2025-06-30 - 2028-08-31
Participate Sites3Sites
Recruiting3Sites
2024-06-20 - 2027-09-01
Participate Sites6Sites
Recruiting6Sites
2025-10-01 - 2027-10-01
Participate Sites10Sites
Recruiting10Sites
全部
